Actelion Forks Over $250M For Pa. Drugmaker

Law360, New York (August 2, 2013, 6:27 PM EDT) -- Actelion US Holdings Co., a subsidiary of Swiss biotechnology giant Actelion Ltd., will acquire Pennsylvania drugmaker Ceptaris Therapeutics Inc. for a total of $250 million, it was announced Wednesday.

Under the deal, Actelion said it has paid Ceptaris $25 million upon signing of the merger agreement and will pay Ceptaris’ shareholders $225 million upon the closing of the transaction, according to a company statement.

However, the deal is contingent on Ceptaris’ chief product Valchlor, a topical drug intended to treat a form of cancer, securing approval...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.